Compare Stocks: DNLI, BEAM, HALO, and BBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$65.80 -0.3%	$76.79	$51.85 ▼ $93.42	$12.90B	0.97	2.71 million shs	2.80 million shs
BEAM Beam Therapeutics	$24.45 -0.3%	$26.71	$20.23 ▼ $38.26	$2.53B	2.22	1.93 million shs	1.56 million shs
DNLI Denali Therapeutics	$20.67 -0.7%	$22.96	$13.75 ▼ $27.30	$3.33B	1.01	1.67 million shs	2.26 million shs
HALO Halozyme Therapeutics	$110.40 -1.0%	$102.42	$61.22 ▼ $116.85	$12.66B	0.88	2.30 million shs	3.51 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-0.26%	+0.14%	-14.09%	-14.76%	+26.68%
BEAM Beam Therapeutics	-0.29%	+0.33%	-16.92%	-29.72%	+0.74%
DNLI Denali Therapeutics	-0.67%	+1.03%	-13.01%	-19.98%	+42.36%
HALO Halozyme Therapeutics	-1.04%	-1.81%	+3.67%	+38.96%	+50.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$65.80 -0.3%	$76.79	$51.85 ▼ $93.42	$12.90B	0.97	2.71 million shs	2.80 million shs
BEAM Beam Therapeutics	$24.45 -0.3%	$26.71	$20.23 ▼ $38.26	$2.53B	2.22	1.93 million shs	1.56 million shs
DNLI Denali Therapeutics	$20.67 -0.7%	$22.96	$13.75 ▼ $27.30	$3.33B	1.01	1.67 million shs	2.26 million shs
HALO Halozyme Therapeutics	$110.40 -1.0%	$102.42	$61.22 ▼ $116.85	$12.66B	0.88	2.30 million shs	3.51 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-0.26%	+0.14%	-14.09%	-14.76%	+26.68%
BEAM Beam Therapeutics	-0.29%	+0.33%	-16.92%	-29.72%	+0.74%
DNLI Denali Therapeutics	-0.67%	+1.03%	-13.01%	-19.98%	+42.36%
HALO Halozyme Therapeutics	-1.04%	-1.81%	+3.67%	+38.96%	+50.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.83	Moderate Buy	$102.61	55.94% Upside
BEAM Beam Therapeutics	2.79	Moderate Buy	$49.00	100.41% Upside
DNLI Denali Therapeutics	2.75	Moderate Buy	$35.85	73.42% Upside
HALO Halozyme Therapeutics	2.62	Moderate Buy	$91.20	-17.39% Downside

Current Analyst Ratings Breakdown

Latest DNLI, BEAM, HALO, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	BBIO BridgeBio Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
9/23/2026	BEAM Beam Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/10/2026	BBIO BridgeBio Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
9/10/2026	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/9/2026	BEAM Beam Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
9/2/2026	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/2/2026	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/2/2026	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00
9/1/2026	BBIO BridgeBio Pharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$96.00 ➝ $110.00
8/31/2026	HALO Halozyme Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/25/2026	DNLI Denali Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$30.00 ➝ $35.00

(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$502.08M	25.62	N/A	N/A	($10.77) per share	-6.11
BEAM Beam Therapeutics	$139.74M	18.07	N/A	N/A	$12.20 per share	2.00
DNLI Denali Therapeutics	$330.53M	10.00	N/A	N/A	$6.91 per share	2.99
HALO Halozyme Therapeutics	$1.40B	8.97	$4.72 per share	23.38	$0.42 per share	262.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$724.93M	-$3.57	N/A	N/A	N/A	-97.03%	N/A	-61.19%	10/28/2026 (Estimated)
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
DNLI Denali Therapeutics	-$512.54M	-$2.84	N/A	N/A	N/A	N/A	-55.27%	-44.24%	11/5/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	32.96	11.83	0.42	24.86%	260.98%	23.91%	11/2/2026 (Estimated)

Latest DNLI, BEAM, HALO, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/28/2026	Q3 2026	BBIO BridgeBio Pharma	-$0.6131	N/A	N/A	N/A	$268.99 million	N/A
8/10/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.5756	-$0.78	-$0.2044	-$0.78	$220.91 million	$243.68 million
8/6/2026	Q2 2026	DNLI Denali Therapeutics	-$0.5131	-$0.68	-$0.1670	-$0.68	$2.15 million	$3.60 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	1.23	1.17
BEAM Beam Therapeutics	0.09	14.57	14.57
DNLI Denali Therapeutics	0.01	8.37	8.32
HALO Halozyme Therapeutics	13.50	2.71	2.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BEAM Beam Therapeutics	99.68%
DNLI Denali Therapeutics	92.92%
HALO Halozyme Therapeutics	97.79%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	14.23%
BEAM Beam Therapeutics	3.80%
DNLI Denali Therapeutics	9.70%
HALO Halozyme Therapeutics	2.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	839	195.49 million	167.67 million	Optionable
BEAM Beam Therapeutics	540	103.29 million	99.36 million	Optionable
DNLI Denali Therapeutics	507	159.85 million	144.34 million	Optionable
HALO Halozyme Therapeutics	423	113.50 million	110.66 million	Optionable

DNLI, BEAM, HALO, and BBIO Headlines

Recent News About These Companies

Halozyme Therapeutics Adds James Daly to Board

September 30 at 4:51 PM | tipranks.com

Halozyme Announces Appointment of Jim Daly to its Board of Directors

September 30 at 4:05 PM | prnewswire.com

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages

September 30 at 2:15 AM | americanbankingnews.com

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Rated "Moderate Buy" by Sell-Side Brokerages

September 30 at 2:13 AM | marketbeat.com

Biogen (NASDAQ:BIIB) Q2 earnings: Leading the therapeutics pack

September 25, 2026 | msn.com

Why Women-Run Companies Deserve a Place in Your Portfolio

September 24, 2026 | zacks.com

Head to Head Review: Halozyme Therapeutics (NASDAQ:HALO) & Co-Diagnostics (NASDAQ:CODX)

September 24, 2026 | defenseworld.netD

Halozyme Therapeutics (NASDAQ:HALO) Sets New 12-Month High - Time to Buy?

September 24, 2026 | americanbankingnews.com

Halozyme Therapeutics (NASDAQ:HALO) Reaches New 12-Month High - Here's Why

September 24, 2026 | marketbeat.com

Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns

September 23, 2026 | zacks.com

Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?

September 23, 2026 | zacks.com

Halozyme Raises $1.5 Billion via Convertible Notes Offering

September 22, 2026 | tipranks.com

Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost?

September 20, 2026 | insidermonkey.com

Halozyme Therapeutics stock edges higher as investors weigh Q2 growth and pipeline risk

September 20, 2026 | ad-hoc-news.deA

Halozyme Therapeutics Director Posard Matthew L. Sells 18,996 Shares at Prices Up to $108.99

September 19, 2026 | kalkinemedia.comK

Halozyme Announces Upsized Pricing Of $1.3 Bln Convertible Senior Notes Due 2033

September 18, 2026 | rttnews.com

Halozyme Therapeutics (NASDAQ:HALO) Hits New 12-Month High - Should You Buy?

September 18, 2026 | marketbeat.com

Halozyme Prices Upsized $1.3 Billion Convertible Notes Offering

September 18, 2026 | tipranks.com

Halozyme prices $1.3B convertible notes offering due 2033

September 18, 2026 | streetinsider.com

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033

September 17, 2026 | prnewswire.com

Matthew Posard Sells 18,996 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

September 17, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI, BEAM, HALO, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$65.80 -0.17 (-0.26%)

Closing price 09/30/2026 04:00 PM Eastern

Extended Trading

$66.12 +0.32 (+0.49%)

As of 09/30/2026 07:56 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Beam Therapeutics NASDAQ:BEAM

$24.45 -0.07 (-0.29%)

Closing price 09/30/2026 04:00 PM Eastern

Extended Trading

$24.77 +0.32 (+1.30%)

As of 09/30/2026 07:56 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$20.67 -0.14 (-0.67%)

Closing price 09/30/2026 04:00 PM Eastern

Extended Trading

$21.02 +0.35 (+1.71%)

As of 09/30/2026 07:30 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Halozyme Therapeutics NASDAQ:HALO

$110.40 -1.16 (-1.04%)

Closing price 09/30/2026 04:00 PM Eastern

Extended Trading

$110.44 +0.03 (+0.03%)

As of 09/30/2026 07:58 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DNLI, BEAM, HALO, and BBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DNLI, BEAM, HALO, and BBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DNLI, BEAM, HALO, and BBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI, BEAM, HALO, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

Beam Therapeutics NASDAQ:BEAM

Denali Therapeutics NASDAQ:DNLI

Halozyme Therapeutics NASDAQ:HALO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DNLI, BEAM, HALO, and BBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DNLI, BEAM, HALO, and BBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DNLI, BEAM, HALO, and BBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI, BEAM, HALO, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

Beam Therapeutics NASDAQ:BEAM

Denali Therapeutics NASDAQ:DNLI

Halozyme Therapeutics NASDAQ:HALO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools